New start-up aims to cut cost of producing proteins for cancer care and diagnostics
A new University of Kent start-up has been launched to commercialize biotechnology that could make it cheaper and easier to produce proteins used in cancer treatments, vaccines and diagnostic tests. Sirius Proteins was registered this month, taking technology developed and patented at Kent a step closer to wider commercial use.
A new University of Kent start-up, Sirius Proteins, aims to make producing proteins for cancer treatments, vaccines, and diagnostic tests cheaper and easier. This venture leverages Vesicle Nucleating Peptide (VNp) technology, developed by Professor Dan Mulvhill and his team at Kent's School of Natural Sciences. VNp works by packaging proteins into membrane-bound vesicles inside bacterial cells, making them easier to produce, collect, and purify.
This innovation could significantly reduce the cost and complexity of producing certain proteins, which are often difficult or expensive to make due to instability, toxicity to bacteria, or specific folding requirements. The technology's potential applications extend beyond medicine to areas like protein engineering, targeted drug delivery, and therapeutic development.
The launch of Sirius Proteins follows research showing VNp's versatility, which could lead to more efficient protein production and potentially more affordable medicines.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
